Scholarlink

Objective <p> <!--Query ID="Q1" Text="Please check if the article title is presented correctly." Resolved="yes"-->This study aims to assess the therapeutic effectiveness and safety of platelet-rich plasma (PRP) in the management of primary and posttraumatic osteoarthritis (OA) patients.</p> Methods <p> <!--Query ID="Q2" Text="Please confirm if the author names and their corresponding affiliations are presented accurately." Resolved="yes"-->A comprehensive literature search was conducted in the following databases: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP database, Wanfang Database, and China Biology Medicine Disc for all double-blind randomized controlled trials (RCTs) on the use of PRP in TOA until November 2025. The data extraction and quality assessment were carried out independently by two researchers. The RevMan5.4 statistical software was used to perform a meta-analysis of the data that met the inclusion criteria.</p> Results <p>Eleven RCTs involving 851 participants were included. PRP injection resulted in a significant improvement in the WOMAC Total score compared to control treatments in primary OA (SMD: -8.53; 95% CI: -14.52 to -2.55; <i>p</i> = 0.005). Subgroup analyses revealed that this benefit was significant in patients younger than 60 years and with both single and double-dose regimens. However, no significant overall effects were observed for the WOMAC Pain, WOMAC Stiffness, VAS, or KOOS subscales. PRP was associated with more transient adverse events, primarily injection-site reactions.</p> Conclusions <p>Intra-articular PRP injection is an effective treatment for improving overall function in patients with primary OA, particularly in younger individuals. While it demonstrates a acceptable safety profile, its effects on specific pain and quality-of-life measures require further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigating the therapeutic impact of platelet-rich plasma on knee, hip, and traumatic osteoarthritis: a meta-analysis and systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月31日

查看全文
  • Shuting Li,
  • Tanguang Wu

摘要

Objective

This study aims to assess the therapeutic effectiveness and safety of platelet-rich plasma (PRP) in the management of primary and posttraumatic osteoarthritis (OA) patients.

Methods

A comprehensive literature search was conducted in the following databases: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP database, Wanfang Database, and China Biology Medicine Disc for all double-blind randomized controlled trials (RCTs) on the use of PRP in TOA until November 2025. The data extraction and quality assessment were carried out independently by two researchers. The RevMan5.4 statistical software was used to perform a meta-analysis of the data that met the inclusion criteria.

Results

Eleven RCTs involving 851 participants were included. PRP injection resulted in a significant improvement in the WOMAC Total score compared to control treatments in primary OA (SMD: -8.53; 95% CI: -14.52 to -2.55; p = 0.005). Subgroup analyses revealed that this benefit was significant in patients younger than 60 years and with both single and double-dose regimens. However, no significant overall effects were observed for the WOMAC Pain, WOMAC Stiffness, VAS, or KOOS subscales. PRP was associated with more transient adverse events, primarily injection-site reactions.

Conclusions

Intra-articular PRP injection is an effective treatment for improving overall function in patients with primary OA, particularly in younger individuals. While it demonstrates a acceptable safety profile, its effects on specific pain and quality-of-life measures require further investigation.